MAM
MRNA icon

Mark Asset Management’s Moderna MRNA Stock Holding History

Mark Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,604
Closed -$1.61M – 56
2023
Q3 		$1.61M Sell
15,604
-26,471
-63% -$2.95M 0.29% 38
2023
Q2 		$5.11M Sell
42,075
-425
-1% -$56.7K 0.83% 31
2023
Q1 		$6.53M Sell
42,500
-1,904
-4% -$314K 1.19% 28
2022
Q4 		$7.98M Buy
44,404
+34,404
+344% +$5.63M 1.81% 22
2022
Q3 		$1.18M Hold
10,000
– – 0.29% 37
2022
Q2 		$1.43M Buy
+10,000
New +$1.43M 0.35% 40
2022
Q1 		– Sell
-27,264
Closed -$6.92M – 54
2021
Q4 		$6.92M Sell
27,264
-23,871
-47% -$6.98M 0.79% 32
2021
Q3 		$19.7M Sell
51,135
-4,210
-8% -$1.55M 2.12% 18
2021
Q2 		$13M Buy
55,345
+27,714
+100% +$4.95M 1.6% 27
2021
Q1 		$3.62M Buy
+27,631
New +$4M 0.54% 40

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mark Asset Management's MRNA Position: Q4 2023 in Review

Mark Asset Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 15,604 shares — an estimated $1.61M sold.

Mark Asset Management first reported a position in MRNA in Q1 2021 and held it in 10 quarters. The position peaked at $19.7M in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Mark Asset Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Mark Asset Management sold 15,604 Moderna shares in Q4 2023, an estimated $1.61M.
  • Mark Asset Management first reported a position in Moderna in Q1 2021 and held it in 10 quarters.
  • Mark Asset Management's Moderna position peaked at $19.7M in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Mark Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.